5HT2A and 5HT2C receptor polymorphisms and predicting clinical response to olanzapine in schizophrenia

J Clin Psychopharmacol. 2002 Dec;22(6):622-4. doi: 10.1097/00004714-200212000-00014.
No abstract available

Publication types

  • Clinical Trial
  • Letter
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Adolescent
  • Adult
  • Aged
  • Antipsychotic Agents / blood
  • Antipsychotic Agents / therapeutic use*
  • Benzodiazepines
  • Dose-Response Relationship, Drug
  • Humans
  • Middle Aged
  • Olanzapine
  • Pirenzepine / analogs & derivatives*
  • Pirenzepine / blood
  • Pirenzepine / therapeutic use*
  • Polymorphism, Genetic / genetics
  • Psychiatric Status Rating Scales
  • Receptor, Serotonin, 5-HT2A
  • Receptor, Serotonin, 5-HT2C
  • Receptors, Serotonin / genetics*
  • Receptors, Serotonin / metabolism
  • Schizophrenia / drug therapy*
  • Schizophrenia / metabolism
  • Treatment Outcome

Substances

  • Antipsychotic Agents
  • Receptor, Serotonin, 5-HT2A
  • Receptor, Serotonin, 5-HT2C
  • Receptors, Serotonin
  • Benzodiazepines
  • Pirenzepine
  • Olanzapine